Abeona Therapeutics Inc. financial data

Symbol
ABEO on Nasdaq
Industry
Pharmaceutical Preparations
Location
6555 Carnegie Ave, 4 Th Floor, Cleveland, OH
State of incorporation
DE
Fiscal year end
December 31
Former names
PLASMATECH BIOPHARMACEUTICALS INC (to 6/4/2015), ACCESS PHARMACEUTICALS INC (to 8/14/2014), CHEMEX PHARMACEUTICALS INC (to 2/5/1996)
Latest financial report
10-K - Q4 2024 - Mar 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 637 % +23.3%
Debt-to-equity 184 % -30.4%
Return On Equity -165 % +50.4%
Return On Assets -58.2 % +36.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 48.5M shares +77.4%
Common Stock, Shares, Outstanding 45.6M shares +72.1%
Entity Public Float 171M USD +118%
Common Stock, Value, Issued 457K USD +72.5%
Weighted Average Number of Shares Outstanding, Basic 41M shares +92%
Weighted Average Number of Shares Outstanding, Diluted 41M shares +92%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3.5M USD +250%
Research and Development Expense 34.4M USD +10.5%
General and Administrative Expense 29.9M USD +57.1%
Operating Income (Loss) -64.2M USD -36.2%
Nonoperating Income (Expense) 1.19M USD -59.4%
Net Income (Loss) Attributable to Parent -63.7M USD -17.6%
Earnings Per Share, Basic -1.55 USD/shares +38.7%
Earnings Per Share, Diluted -1.55 USD/shares +38.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 23.4M USD +61.4%
Cash, Cash Equivalents, and Short-term Investments 98.1M USD +86.5%
Accounts Receivable, after Allowance for Credit Loss, Current 3.5M USD +250%
Assets, Current 101M USD +80.9%
Property, Plant and Equipment, Net 4.43M USD +25.4%
Operating Lease, Right-of-Use Asset 3.55M USD -20.3%
Other Assets, Noncurrent 96K USD -65.3%
Assets 109M USD +70.2%
Accounts Payable, Current 3.44M USD +85.2%
Accrued Liabilities, Current 6.33M USD +5.82%
Liabilities, Current 16.6M USD +23.6%
Operating Lease, Liability, Noncurrent 3.26M USD -25.9%
Liabilities 64.9M USD +32%
Accumulated Other Comprehensive Income (Loss), Net of Tax 8K USD
Retained Earnings (Accumulated Deficit) -813M USD -8.5%
Stockholders' Equity Attributable to Parent 44M USD +197%
Liabilities and Equity 109M USD +70.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.5M USD -23.8%
Net Cash Provided by (Used in) Financing Activities 25.4M USD
Net Cash Provided by (Used in) Investing Activities -7.82M USD -454%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 45.6M shares +72.1%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.09M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 23.7M USD +60%
Interest Paid, Excluding Capitalized Interest, Operating Activities 607K USD
Deferred Tax Assets, Valuation Allowance 114M USD +4.97%
Deferred Tax Assets, Gross 114M USD +4.97%
Operating Lease, Liability 4.09M USD -24.4%
Depreciation 700K USD -12.5%
Payments to Acquire Property, Plant, and Equipment 725K USD +233%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -63.7M USD -17.6%
Lessee, Operating Lease, Liability, to be Paid 4.97M USD -25.5%
Property, Plant and Equipment, Gross 19.4M USD +17.5%
Operating Lease, Liability, Current 823K USD -17.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 791K USD -49.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 853K USD -14.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 882K USD -30.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 807K USD +2.02%
Deferred Tax Assets, Operating Loss Carryforwards 88.1M USD +11.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 823K USD +1.98%
Additional Paid in Capital 857M USD +12.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 491K USD -25.7%
Share-based Payment Arrangement, Expense 6.63M USD +39%
Interest Expense 4.21M USD +907%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%